

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/82937 A1

(51) International Patent Classification⁷: A61K 31/74, 38/46, 38/48, 9/70, 9/14, 38/00, 47/30, 47/32, 47/34, 47/00

(21) International Application Number: PCT/US01/13520

(22) International Filing Date: 26 April 2001 (26.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/200,457 28 April 2000 (28.04.2000) US
60/200,637 28 April 2000 (28.04.2000) US

(71) Applicant: FZIOMED, INC. [US/US]; 170 Unit A
Granada Drive, San Luis Obispo, CA 93401 (US).

(72) Inventors: CORTESE, Stephanie, M.; 5330 Pescado
Lane, Atascadero, CA 93422 (US). SCHWARTZ, Her-
bert, E.; 150 Montalvo Road, Redwood City, CA 94062
(US). OPPELT, William, G.; 348 Miller Way, Arroyo
Grande, CA 93420 (US).

(74) Agents: MEYER, Sheldon, R. et al.; Fliesler Dubb Meyer
and Lovejoy LLP, Suite 400, Four Embarcadero Center,
San Francisco, CA 94111-4156 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/82937 A1

(54) Title: HEMOSTATIC COMPOSITIONS OF POLYACIDS AND POLYALKYLENE OXIDES AND METHODS FOR THEIR USE

(57) **Abstract:** The present invention relates to improved methods for making and using hemostatic, bioadhesive, bioresorbable, anti-adhesion compositions made of intermacromolecular complexes of carboxyl-containing polysaccharides, polyether, polyacids, polyalkylene oxides, and optionally including multivalent cations and/or polycations and/or hemostatic agents. The polymers can be associated with each other, and are then either dried into membranes or sponges, or are used as fluids, gels, or foams. Hemostatic, bioresorbable, bioadhesive, anti-adhesion compositions are useful in surgery to prevent bleeding and the formation and reformation of post-surgical adhesions. The compositions are designed to breakdown *in-vivo*, and thus be removed from the body. The hemostatic, anti-adhesion, bioadhesive, bioresorptive, antithrombogenic and/or physical properties of such compositions can be varied as needed by carefully adjusting the pH, solids content cation content of the polymer casting solutions, polyacid composition, the polyalkylene oxide composition, or by adding hemostatic agents. Hemostatic membranes, gels and/or foams can be used concurrently. Hemostatic, antiahesion compositions may also be used to lubricate tissues and/or medical instruments, and/or deliver drugs to the surgical site and release them locally.

**HEMOSTATIC COMPOSITIONS OF POLYACIDS AND
POLYALKYLENE OXIDES AND METHODS FOR THEIR USE**

5

RELATED CASES

This application claims priority under 35 U.S.C. § 120 to United States Provisional Patent Application Serial No: 60/200,457, filed April 28, 2000, United 10 States Provisional Patent Application Serial No: 60/200,637, filed April 28, 2000, and to U.S. Utility Patent Application Serial No: 09/472,110, filed December 27, 1999, all patent applications herein incorporated fully by reference. This application is also related to United States Utility Patent Application titled "Polyacid/Polyalkylene Oxide Foams and Gels and Methods for Their Delivery", 15 Mark E. Miller, Stephanie M. Cortese, Herbert E. Schwartz, and William G. Oppelt, inventors, Attorney docket No: FZIO 6604 US0 SRM/DBB, filed concurrently, incorporated herein fully by reference.

FIELD OF THE INVENTION

20 This invention relates generally to the delivery and use of polyacid/polyether complexes, cross-linked gels comprising polyacids, polyalkylene oxides and multivalent ions, the use of those compositions and gels to inhibit the formation of adhesions between tissues and to promote hemostasis.

25

BACKGROUND OF THE INVENTION

Adhesions are unwanted tissue growths occurring between layers of adjacent bodily tissue or between tissues and internal organs. Adhesions commonly form during the healing which follows surgical procedures, and when present, adhesions can prevent the normal motions of those tissues and organs with 30 respect to their neighboring structures.

Bleeding at a site of surgery or a wound can contribute to adhesion formation. Adherence of platelets and/or fibrin clots can promote scarring and the formation of fibrous tissue or undesired adhesions between tissues. Thus, it can be important to reduce post-surgical bleeding by providing hemostasis.

5 Additionally, it can be important to prevent fibrin clots from forming on adjacent tissues (antithrombogenesis). Antithrombogenicity and hemostasis are not the same phenomena. Antithrombogenicity is a property of a surface to inhibit the adherence and/or activation of platelets on that surface. Hemostasis is a complex set of physiological events within blood vessels that ultimately can result in the

10 cessation of blood flow due to hemorrhage. Antithrombogenicity can be an important part of hemostasis, in that often an early event in hemostasis includes the adherence of platelets to a cut tissue, with subsequent clot formation at that site. Once a clot forms, it can occlude the opening in the blood vessel, thereby decreasing leakage of blood out of the blood vessel. Although formation of clots

15 (thrombi) within and immediately around an injured blood vessel is often desirable, if bleeding extends to the surrounding tissues, clot formation at those more remote sites can be harmful and does not necessarily contribute to hemostasis.

The medical and scientific communities have studied ways of reducing the formation of post-surgical adhesions by the use of high molecular weight carboxyl-containing biopolymers. These biopolymers can form hydrated gels which act as physical barriers to separate tissues from each other during healing, so that adhesions between normally adjacent structures do not form. After healing has substantially completed, the barrier is no longer needed, and should be eliminated from the body to permit more normal function of the affected tissues.

20 25 Several different types of biopolymers have been used for this purpose. For example, Balazs et al., U.S. Pat. No. 4,141,973 discloses the use of a hyaluronic acid (HA) fraction for the prevention of adhesions. However, because HA is

relatively soluble and readily degraded *in vivo*, it has a relatively short half-life *in vivo* of 1 to 3 days, which limits its efficacy as an adhesion preventative.

Methyl cellulose and methyl cellulose derivatives are also known to reduce the formation of adhesions and scarring that may develop following surgery.

5 (Thomas E. Elkins, et al., *Adhesion Prevention by Solutions of Sodium Carboxymethylcellulose in the Rat, Part I*, Fertility and Sterility, Vol. 41, No. 6, June 1984; Thomas E. Elkins, M.D. et al., *Adhesion Prevention by Solutions of Sodium Carboxymethylcellulose in the Rat, Part II*, Fertility and Sterility, Vol. 41, No. 6, June 1984. However, these solutions are rapidly reabsorbed by the body and 10 disappear from the surgical site.

Additionally, solutions of polyethers can also decrease the incidence of post-surgical adhesions. Pennell et al., U.S. Patent No. 4,993,585 describes the use 15 of polyethylene oxide in solutions of up to 15% to decrease formation of post-surgical adhesions. Pennell et al., U.S. Patent No. 5,156,839 describes the use of mixtures of carboxymethylcellulose up to about 2.5 % by weight, and polyethylene oxide, in concentrations of up to about 0.5% by weight in physiologically acceptable, pH neutral mixtures. Because of the neutral pH, these materials do not form association complexes, and thus, being soluble, are cleared from the body within a short period of time.

20 Although certain carboxypolysaccharide-containing membranes have been described, prior membranes can have disadvantages for use to prevent adhesions under certain conditions. Butler, U.S. Patent No. 3,064,313 describes the manufacture of films made of 100% carboxymethylcellulose (CMC) with a degree of substitution of 0.5 and below, made insoluble by acidifying the solution to pH 25 of between 3 and 5, and then drying the mixture at 70°C to create a film. These films were not designed to be used as anti-adhesion barriers.

Anderson, U.S. Patent No. 3,328,259 describes making films of water soluble cellulose compounds, alkali metal salts, and a plasticizing agent for use as

external bandages. These materials are rapidly soluble in plasma and water and thus would have a very short residence time as an intact film. Therefore, these compositions are not suitable for alleviating surgical adhesions.

Smith et al., U.S. Patent No. 3,387,061 describes insoluble association complexes of carboxymethylcellulose and polyethylene oxide made by lowering the pH to below 3.5 and preferably below 3.0, and then drying and baking the resulting precipitate (see Example XXXVIII). These membranes were not designed for surgical use to alleviate adhesions. Such membranes are too insoluble, too stiff, and swell to little to be ideal for preventing post-surgical adhesions.

Burns et al., U.S. Patent No. 5,017,229 describes water insoluble films made of hyaluronic acid, carboxymethyl cellulose, and a chemical cross-linking agent. Because of the covalent cross-linking with a carbodiimide, these films need extensive cleaning procedures to get rid of the excess cross-linking agent; and because they are made without a plasticizer, they are too stiff and brittle to be ideally suited for preventing adhesions -- they do not readily conform to the shapes of tissues and organs of the body.

Thus, there is a need for antiadhesion membranes and gels that can be used under a variety of different circumstances. D. Wiseman reviews the state of the art of the field in *Polymers for the Prevention of Surgical Adhesions*, In: *Polymeric Site-specific Pharmacotherapy*, A.J. Domb, Ed., Wiley & Sons, (1994). A currently available antiadhesion gel is made of ionically cross-linked hyaluronic acid. (Huang et al., U.S. Pat. No. 5,532,221, incorporated herein fully by reference).

Ionic cross-linking of polysaccharides is well documented in the chemical and patent literature (Morris and Norton, *Polysaccharide Aggregation in Solutions and Gels*, Ch. 19, in *Aggregation Processes in Solution*, Wyn-Jones, E. and Gormally, J, Eds., Elsevier Sci. Publ. Co. NY (1983)). Each type of metal ion can

be used to form gels of different polymers under specific conditions of pH, ionic strength, ion concentration and concentrations of polymeric components. For example, alginate (a linear 1,4 - linked beta-D-mannuronic acid, alpha-L-glucuronic acid polysaccharide) can form association structures between 5 polyglucuronate sequences in which divalent calcium ions can bind, leading to ordered structures and gel formation. Similar calcium binding ability is also demonstrated by pectin which has a poly-D-galacturonate sequence. The order of selectivity of cations for pectins is $Ba^{2+} > Sr^{2+} > Ca^{2+}$. CMC also can bind to monovalent and divalent cations, and CMC solutions can gel with the addition of 10 certain trivalent cations (*Cellulose Gum*, Hercules, Inc., page 23 (1984)).

Sayce et al. (U.S. Pat. No. 3,969,290) discloses an air freshener gel comprising CMC and trivalent cations such as chromium or aluminum.

Smith (U.S. Pat. No. 3,757,786) describes synthetic surgical sutures made from water-insoluble metal salts of cellulose ethers.

15 Shimizu et al. (U.S. Pt. No. 4,024,073) describe hydrogels consisting of water-soluble polymers such as dextran and starch chelated with cystine or lysine through polyvalent cations.

20 Mason et al. (U.S. Pat. No. 4,121,719) disclose CMC- and gum arabic-aluminum hydrogels used as phosphate binding agents in the treatment of hyperphosphatemia.

U.S. Pat. No. 5,266,326 describes alginate gels made insoluble by calcium chloride. An antiadhesion gel is made of ionically cross-linked hyaluronic acid (Huang et al., U.S. Pat. No. 5,532,221). Cross-linking is created by the inclusion of polyvalent cations, such as ferric, aluminum or chromium salts.

25 Therefore, the prior art discloses no membranes or gels which are ideally suited to the variety of surgical uses of the instant invention.

Pennell et al (U.S. Pat. No. 5,156,839) describes CMC solutions containing small amounts of high molecular weight PEO. In one embodiment, Pennell describes covalently cross-linking gels using dimethylolurea.

Schwartz et al (U.S. Pat. No.s 5,906,997, 6,017,301, and 6,034,140) 5 describe membranes, hydrogels and association complexes of carboxypolysaccharides and polyethers for use as antiadhesion compositions. Because of the presence of polyethers in membranes made using these materials, these compositions exhibited certain antithrombogenic properties, including decreased platelet adhesion, decreased platelet activation, and decreased binding 10 of fibrin and blood clots to membranes. U.S. Patent Application Serial No: 09/472,110, incorporated herein fully by reference, disclosed that multivalent cations including Fe^{3+} , Al^{3+} , and Ca^{2+} , and/or polycations including polylysine and polyarginine can be used to provide intermolecular attraction, thereby providing a means of controlling viscoelastic properties of gels.

15

SUMMARY OF THE INVENTION

Membranes, gels and foams based on association complexation between polyacids ("PA") and hydrophilic polyalkylene oxides ("PO") can exhibit both hemostatic and antithrombogenic properties. In certain embodiments, the materials 20 can have different hemostatic properties depending upon the pH and the PA and PO contents of the compositions. The PA of this invention can be made with polyacrylic acid, carboxypolysaccharides such as CMC, and other polyacids known in the art. Ionically and non-ionically cross-linked gels of this invention can be made by mixing polyacid and polyether together, either in dry form or in aqueous 25 solution, and adding a solution containing cations to provide cross-linking between the PA, the PO and the cations. The cations can be either H^+ or multivalent cations including divalent and trivalent cations. The pH of the compositions can be adjusted to provide a desired degree of hemostatic effect. In certain embodiments,

more acidic compositions can provide increased hemostasis. The membranes, gels and foams can then be sterilized and stored before use.

One aspect of the invention is a composition comprising an intermacromolecular association of a carboxypolysaccharide (CPS) and a polyether 5 (PE), and, for example, a polyethylene glycol ("PEG") which exhibits both adhesion properties as well as hemostatic properties.

Another aspect of the invention comprises foams and methods of manufacturing foams from complexes of PA and PO.

Another aspect of this invention includes PA/PO compositions which can 10 be delivered as a spray, or can be dried into a sponge and delivered to a tissue.

The compositions of this invention can be used to inhibit post-surgical adhesions, to decrease the consequences of arthritis, and/or to provide a lubricant for numerous medical and/or veterinary uses.

Additionally, in accordance with some aspects of the invention, drugs can 15 be included in the membranes or gels to deliver pharmacological compounds directly to the tissues. Certain of these embodiments can include the use of thrombin or other hemostatic agents to inhibit bleeding at a surgical or wound site.

In certain embodiments, the compositions can be sterilized using thermal methods, gamma irradiation, and ion beams which can alter the physical and other 20 properties of the components. Alternatively, in other embodiments of this invention, the materials can be filter sterilized.

The materials are biocompatible, and are cleared from the body within a desired period of time, which can be controlled.

By using both gel compositions and membrane compositions together in the 25 same treatment procedure, improved anti-adhesion properties can be achieved.

DETAILED DESCRIPTIONDEFINITIONS

Before describing the invention in detail, the following terms are defined as used herein.

5 The term "adhesion" means abnormal attachments between tissues and organs that form after an inflammatory stimulus such as surgical trauma.

The terms "adhesion prevention" and "anti-adhesion" means preventing or inhibiting the formation of post-surgical scar and fibrous bands between traumatized tissues, and between traumatized and nontraumatized tissues.

10 The term "antithrombogenic" means decreased adherence of platelets, decreased platelet activation, decreased fibrin adherence, and/or decreased blood clot adherence to the anti-adhesion composition.

The term "association complex" or "intermacromolecular complex" means the molecular network formed between polymers containing CPS, polyacids, PE, 15 polyalkylene oxide and/or multivalent ions, wherein the network is cross-linked through hydrogen and/or ionic bonds.

The term "bioadhesive" means being capable of adhering to living tissue.

The term "bioresorbable" means being capable of being reabsorbed and eliminated from the body.

20 The term "biocompatible" means being physiologically acceptable to a living tissue and organism.

The term "carboxymethylcellulose" ("CMC") means a polymer composed of repeating carboxylated cellobiose units, further composed of two anhydroglucose units (β -glucopyranose residues), joined by 1,4 glucosidic linkages.

25 The cellobiose units are variably carboxylated.

The term "carboxypolysaccharide" ("CPS") means a polymer composed of repeating units of one or more monosaccharides, and wherein at least one of the monosaccharide units has a hydroxyl residue substituted with a carboxyl residue.

The term "chemical gel" means a gel network comprised of covalently cross-linked polymers.

The term "degree of substitution" ("d.s.") means the average number of carboxyl or other anionic residues present per mole of cellobiose or other polymer.

5 The term "discectomy" means a surgical operation whereby a ruptured vertebral disc is removed.

The term "endoscope" means a fiber optic device for close observation of tissues within the body, such as a laparoscope or arthroscope.

The term "fibrous tissue" means a scar or adhesions.

10 The term "foam" means a gel having bubbles of a foaming gas.

The term "gel pH" means the pH of the gel or the pH of the casting solution from which the gel or a partially dried form of the gel is formed.

The term "hemostasis" means cessation of bleeding from a surgical or trauma site.

15 The term "hemostatic agent" means a drug or chemical that promotes hemostasis.

The term "hyaluronic acid" ("HA") means an anionic polysaccharide composed of repeat disaccharide units of N-acetylglucosamine and glucuronic acid. HA is a natural component of the extracellular matrix in connective tissue.

20 The term "hydration" (also "swelling") means the process of taking up solvent by a polymer solution.

The term "hydrogel" means a three-dimensional network of hydrophilic polymers in which a large amount of water is present.

25 The term "laminectomy" means a surgical procedure wherein one or more vertebral lamina are removed.

The term "mesothelium" means the epithelium lining the pleural, pericardial and peritoneal cavities.

The term "peritoneum" means the serous membrane lining the abdominal cavity and surrounding the viscera.

5 The terms "physical gel," "physical network" and "pseudo gel" mean non-covalently cross-linked polymer networks wherein the association of polymers in these gels is characterized by relatively weak and potentially reversible chain-chain interactions, which can be comprised of hydrogen bonding, ionic association, ionic bonding, hydrophobic interaction, cross-linking by crystalline segments, and/or solvent complexation.

10 The term "polyacid" ("PA") means molecules comprising subunits having dissociable acidic groups.

The term "polyalkylene oxide" ("PO") means non-ionic polymers comprising alkylene oxide monomers. Examples of polyalkylene oxides include polyethylene oxide (PEO), polypropylene oxide (PPO) and polyethylene glycol (PEG), or block copolymers comprising PO and/or PPO.

15 The term "polycation" means a polymer containing multiple positively charged moieties. Examples of polycations include polylysine, polyarginine, and chitosan.

20 The term "polyethylene glycol" ("PEG") means a non-ionic polyether polymer being composed of ethylene oxide monomers, and having a molecular weight in the range of about 200 daltons ("d") to about 5000 daltons.

The term "polyethylene oxide" ("PEO") means the non-ionic polyether polymer composed of ethylene oxide monomers. The molecular weight of PEO as used herein is between 5,000 d and 8,000 kilodaltons ("kd").

25 The term "solids" used with reference to polymer compositions means the total polymer content as a weight percentage of the total weight of the composition.

The term "solids ratio" means the percentage of the total dry polymer contents as a weight percentage of the total solids content.

The term "tissue ischemia" means deprivation of blood flow to living tissues.

5

DETAILED DESCRIPTION OF THE INVENTION

Certain embodiments of the present invention are directed to compositions and methods of promoting hemostasis, reducing the formation of adhesions during and following surgery and/or wound healing comprising the step of delivering to a wound or a tissue, an implantable, hemostatic, bioresorbable association complex 10 of carboxypolysaccharides (CPS) or other polyacid (PA), a polyalkylene oxide (PO), such as a polyether (PE), a polyethylene glycol (PEG), and/or multivalent ions and/or polycations. Complexes in membrane form can generally be made by mixing appropriate amounts and compositions of CPS and PE together in solution, then, adjusting the pH to provide a desired degree of hemostasis. Gels and foams 15 can be used either at neutral pH, slightly alkaline, or at acidic pH.

To form foams, the hydrogel or association complex can be charged with a gas at increased pressure. Upon releasing the pressure, the dissolved gas expands 20 to create the foam. The foam is applied to the surgical site, and adheres to the tissues which, during wound healing, would otherwise tend to form adhesions between them. Some of the gas escapes from the foam and the foam returns to a more gel-like state. The complex remains at the site for different periods of time, depending upon its composition, method of manufacture, and upon 25 post-manufacture conditioning. When the tissues have substantially healed, the complex then degrades and/or dissolves and is cleared from the body.

25 A possible mechanism for formation of cross-linked gels and foams of this invention is discussed in U.S. Patent 5,906,997, incorporated herein fully by reference. This possible mechanism involves the formation of hydrogen bonds between PA and PO moieties in solution. Further, adding multivalent cations can

form additional, ionic bonding between the PA, PO and cations. These possible mechanisms are for illustration only, and are not intended to be limiting. Other mechanisms may be responsible for the effects of the compositions of this invention.

5

Compositions of Hemostatic Membranes, Gels and Foams

The carboxypolysaccharide, polyether and other components of the compositions of this invention may be of any biocompatible sort, including but not limited to those described in U.S. Patent 5,906,997 and U.S. Patent Application 10 Serial No: 09/472,110.

The pH of the compositions of the present invention may be below about 7, between 1 and 7, alternatively between 2 and 7, in other embodiments, between 2.5 and 7, in other embodiments, between 3 and 7, and in yet other embodiments, between 3.5 and 6.0. For certain uses, a pH of about 4.1 is desired where there is 15 a desirable balance between the bioadhesiveness, hemostasis, antiadhesion properties, the rates of bioresorbability and the biocompatibility for several uses contemplated in the present invention.

Like other polymers which are known to swell when exposed to water, PA/PO gels and foams are also bioadhesive. A possible reason for this 20 phenomenon is that with increased hydration, more charges on the polyacid become exposed, and therefore may be made available to bind to tissue proteins. However, excessive hydration is detrimental to bioadhesion. Thus, a means of controlling the bioadhesiveness of membranes is to control their hydration properties.

25 In addition to decreasing the pH of the association complex, increased intermacromolecular association can be achieved using carboxylated PAs, such as CPSs, with increased degree of carboxyl substitution. By increasing the density of protonatable carboxyl residues on the CPS, there is increasing likelihood of

hydrogen bond formation even at a relatively high pH. The degree of substitution of CPS must be greater than 0, i.e., there must be some carboxyl residues available for hydrogen bond formation. However, the upper limit is theoretically 3 for cellulose derivatives, wherein for each mole of the saccharide, 3 moles of carboxyl 5 residues may exist. Thus, in the broadest application of the invention involving CPS as the polyacid, the d.s. is greater than 0 and up to and including 3. In other embodiments, the d.s. is between 0.3 and 2. CPS with d.s. between 0.5 and 1.7 work well, and CPSs with a d.s. of about 0.65-1.45 work well and are commercially available.

10 The complexes of the instant invention are intended to have a finite residence time in the body. Once placed at a surgical or wound site, or site of inflammation, the foam is designed to serve as a hemostatic barrier for a limited time period. Once healing has substantially taken place, the anti-adhesion barrier naturally disintegrates, and the components are cleared from the body. The time 15 taken to clear the body for certain embodiments is desirable no more than 29 days because of increased regulation by the Food and Drug Administration of devices intended to remain within the body for more than 30 days. However, it can be desirable to provide longer-duration compositions for certain long-term uses.

20 The mechanisms for bioresorption of PA/PO complexes are not well understood. However, an early step in the process of bioresorption is solubilization of the network of polyacid and polyalkylene oxide. For example, when soluble, CMC and PEO can diffuse into the circulation and be carried to the liver and kidneys, where they may be metabolized or otherwise eliminated from the body. Additionally, enzymatic action can degrade carbohydrates. It is possible that 25 enzymes contained in neutrophils and other inflammatory cells may degrade the polymer networks and thereby increase the rate of elimination of the components from the body.

The degradation and rate of solubilization and disruption of the membrane is manipulated by careful adjustment of the pH during formation of the association complexes, by varying the CPS/PE ratio, and by selecting the appropriate degree of substitution of the CPS and molecular weights of the PE and CPS. Decreasing 5 the molecular weight of CPS increases its solubility. The strength of the membrane can be tailored to the surgical application. For example, certain surgical applications (e.g., spine or tendon) may require a stronger, more durable membrane than others (such as intraperitoneal applications). Manipulation of the above-mentioned experimental variables allows the manufacture and use of 10 products with variable residence times in the body.

Biocompatibility of CPS/PE complexes of the present invention can be a function of its acidity. A highly acidic complex contributes a relatively larger total acid load to a tissue than does a more neutral complex. Additionally, the more rapidly hydrogen ions dissociate from a complex, the more rapidly physiological 15 mechanisms must compensate for the acid load by buffering, dilution and other mechanisms. To mimic the rate and total amount of acid given up by a membrane *in vivo*, membranes are placed in PBS solutions and the degree of acidification of the PBS is measured. In addition to membrane pH, membrane composition also influences the acid load delivered to the body. Moreover, by using a foam 20 preparation, the total solids content of the antiadhesion dose can be less than for either non-foam gels or for membranes. Therefore, the total load of acid delivered to a tissue by an acidic foam can be reduced, decreasing any adverse effects of the composition's acidity.

25 **Ionically and Non-Ionically Cross-Linked Polyacid/Polyalkylene Oxide Gels and Foams**

Other embodiments of the present invention are directed to ionically and non-ionically cross-linked membranes, gels and foams for reducing surgical

adhesions, decreasing the symptoms of arthritis, and providing biologically compatible lubricants. Methods for accomplishing these aims comprise the step of delivering to a wound or other biological site, an implantable, bioresorbable composition comprised of a polyacid and a polyether. The components of the 5 composition can be associated with each other by way of hydrogen bonding, ionic bonding, ionic association or ionic cross-linking, although other mechanisms may be responsible for the association.

Certain embodiments having relatively little intermolecular ionic bonding can be more readily resorbed than embodiments having more bonding. Thus, 10 increasing intermolecular bonding can increase residence time of the composition in the body, and therefore can remain at the site for a longer period of time than compositions having smaller degrees of intermolecular bonding. By way of example, by selecting compositions which provide the highest viscosity (see below), the residence time can be adjusted to provide a desired lifetime of 15 antiadhesion effect. Additionally, in certain other embodiments, the compositions can be dried to form a membrane, which can further increase the residence time at a tissue site. Thus, by selecting the chemical composition of the gel, and by selecting the form of the composition (e.g., gel or membrane), a desired combination of properties can be achieved to suit particular needs.

20

Gel Structures

The gels of this invention are termed "physical gels." The term physical gels has been used (de Gennes, P.G. *Scaling Concepts in Polymer Physics*. Ithaca, 25 NY. Cornell University Press, pp. 133, (1979)) to describe non-covalently cross-linked polymer networks. Physical gels are distinguished from "chemical gels" which are covalently cross-linked. Physical gels are relatively weak and have potentially reversible chain-chain interactions which may be comprised of

hydrogen bonds, ionic association, hydrophobic interaction, stereo-complex formation, cross-linking by crystalline segments, and/or solvent complexation.

Non-ionically and ionically cross-linked gels can be made by mixing appropriate amounts and compositions of polyacids, polyether and optionally, 5 cross-linking cations together in a solution. To form non-ionically associated compositions, the solution can be acidified to promote cross-linking of the polyacid and polyether molecules through hydrogen bonds as described for carboxypolysaccharides and polyethers above and in U.S. Patent No: 5,906,997; U.S. Patent No: 6,017,301; U.S. Patent No.: 6,034,140; U.S. Patent Application 10 No.: 09/252,147, filed February 18, 1999, and U.S. Patent Application No: 09/472,110, filed December 27, 1999. Each aforementioned Patent and Application is herein incorporated fully by reference.

Membranes or films can be made by pouring a solution of PA and PO, with or without multivalent cations onto a suitable flat surface, such as a tray, and 15 permitting the mixture to dry to form a membrane at either reduced (>0.01 Torr) or normal (about 760 Torr) atmospheric pressure. The membranes, films or gels can be placed between tissues which, during wound healing, would form adhesions between them. The complex can remain at the site for different periods of time, depending upon its composition, method of manufacture, and upon 20 post-manufacture conditioning. When the tissues have substantially healed, the complex can then degrade and/or dissolve and is cleared from the body.

Gels and membranes in accordance with the invention can be made with desired degrees of viscosity, rigidity, different rates of bioresorbability, different degrees of bioadhesion, different degrees of anti-adhesion effectiveness and 25 different degrees of hemostatic and antithrombogenic properties.

Compositions of PA and PO require only that the solutions of PA and PO can be handled easily. Dilute solutions (up to about 10% weight/volume) of CPS are easy to handle, and solutions of about 2% CPS are easier to handle. Solutions

of PEO up to about 20% (weight/volume) are possible to make and handle, and solutions of about 1% by weight are easy to handle. However, the maximal concentration can be increased if the molecular weight of the PE is reduced. By way of example only, PEG having a molecular weight of about 1000 Daltons can 5 be made in a concentration of about 50%. Further decreasing the molecular weight of the PE can permit even higher concentrations to be made and handled easily.

B. Polyacid Components

The polyacid may be of any biocompatible sort. By way of example, a 10 group of polyacids useful for the present hemostatic invention are carboxypolysaccharides (CPS) including carboxymethyl cellulose (CMC), carboxyethyl cellulose, chitin, carboxymethyl chitin, hyaluronic acid, alginate, pectin, carboxymethyl dextran, carboxymethyl chitosan, and glycosaminoglycans such as heparin, heparin sulfate, and chondroitin sulfate. Additionally, polyuronic 15 acids such as polymannuronic acid, polyglucuronic acid, and polyguluronic acid, as well as propylene glycol alginate can be used. In addition to the CPS, polyacrylic acids, polyamino acids, polylactic acid, polyglycolic acids, polymethacrylic acid, polyterephthalic acid, polyhydroxybutyric acid, polyphosphoric acid, polystyrenesulfonic acid, and other biocompatible polyacids 20 known in the art are suitable for making foams. Such polyacids are described in *Biodegradable Hydrogels for Drug Delivery*, Park et al., Ed., Technomic Publishing Company, Basel, Switzerland (1993), incorporated herein fully by reference. Preferably, carboxymethylcellulose or carboxyethylcellulose is used. More preferably, carboxymethylcellulose (CMC) is used. The molecular weight 25 of the carboxypolysaccharide can vary from 10 kd to 10,000 kd. CPS in the range of from 600 kd to 1000 kd work well, and CPS of 700 kd works well, and is easily obtained commercially.

C. Polyalkylene Oxide Components

Similarly, many polyalkylene oxides can be used. These include polypropylene oxide (PPO), PEG, and PEO and block co-polymers of PEO and PPO, such as the Pluronics TM (a trademark of BASF Corporation, North Mount 5 Olive, New Jersey). A preferred PO of the present invention is polyethylene oxide (PEO) having molecular weights of between about 5,000 Daltons (d) and about 8,000 Kd. Additionally, polyethylene glycols (PEG) having molecular weights between about 200 d and about 5 kd are useful.

The inclusion of a polyether in the complex confers antithrombogenic 10 properties which help prevent adhesions by decreasing the adherence of blood proteins and platelets to a composition (M. Amiji, *Biomaterials*, 16:593-599 (1995); Merill, E.W., *PEO and Blood Contact in Polyethylene Glycol Chemistry-Biotechnical and Biomedical Applications*, Harris J. M. (ed), Plenum Press, NY, 1992; Chaikof et al., *A.I. Ch.E. Journal* 36(7):994-1002 (1990)). PEO-containing 15 compositions impair the access of fibrin clots to tissue surfaces, even more so than a composition containing CMC alone. The inclusion of PE to the gels also can increase the spreading or coating ability of the gel onto biological tissues. By increasing the spreading, there is increased likelihood that the gel can more efficiently coat more of the tissue and thereby can decrease the likelihood of 20 formation of adhesions at sites remote from the injured tissue.

Varying the ratios and concentrations of the polyacid, the polyether and multivalent cations or polycations can alter hemostatic and antithrombogenic 25 properties. In general, increasing the amount of CPS and decreasing the amount of PO can increase hemostasis, whereas increasing the amount of PO and decreasing the amount of CPS can decrease hemostasis.

The percentage ratio of PA to PO may be from about 10% to 99% by weight, alternatively between about 50% and about 99%, and in another embodiment about 90% to about 99%. Conversely, when the PO is PE, the

percentage of PE can be from about 1% to about 90%, alternatively from about 1% to about 50%, and in another embodiment, about 1% to 10%. In another embodiment, the amount of PE can be about 2.5%.

5.

D. Ionic Components

The tightness of the association and thus the physical properties of ionically associated PA/PO compositions may be closely regulated by selection of appropriate multivalent cations. In certain embodiments, it can be desirable to use 10 cations selected from different groups of the periodic table. Increasing the concentration and/or valence of polyvalent cations can increase ionic bonding. Therefore, trivalent ions of the periodic table such as Fe^{3+} , Al^{3+} , Cr^{3+} can provide stronger ionic cross-linked association complexes than divalent ions such as Ca^{2+} , Mg^{++} , Mn^{++} or Zn^{2+} . However, other cations can be used to cross-link the 15 polymers of the gels of this invention. Polycations such as polylysine, polyarginine, chitosan, or any other biocompatible, polymer containing net positive charges under aqueous conditions can be used. The anions accompanying the cations can be of any biocompatible ion. Typically, chloride (Cl) can be used, but also PO_4^{2-} , HPO_3^{2-} , CO_3^{2-} , HCO_3^- , SO_4^{2-} , borates such as $B_4O_7^{2-}$ and many common anions 20 can be used. Additionally, certain organic polyanions can be used. By way of example, citrate, oxalate and acetate can be used. In certain embodiments, it can be desirable to use hydrated ion complexes, because certain hydrated ion salts can be more easily dissolved than anhydrous salts.

Moreover, in non-ionically associated PA/PO complexes, hydrogen 25 bonding may be a mechanism for associating the polymers together. According to one hypothesis, decreasing the pH of the association complex can increase the amount of hydrogen bonding between PA and PO components. Similarly, increasing the degree of substitution of the carboxypolysaccharide in the gel can

increase cross-linking within the association complex at any given pH or ion concentration. The pH of the membranes and gels can be below about 7.5, alternatively between about 2 and about 7.5, alternatively between about 6 and about 7.5, and in other embodiments, about 3.5 to about 6.

5 Moreover, we unexpectedly found that decreasing the pH of the composition can increase hemostatic effect. Thus, hemostatic compositions can have pH in the range of below about 7.0, alternatively, below about 6.0, in other embodiments below about 5.0, in yet further embodiments below about 4.0, and in still other embodiments, below about 3.0.

10 Membranes and gels having high solids %, or high degrees of cross-linking, such as those made using trivalent cations in the concentration range providing maximal ionic association can dissolve more slowly than gels made with lower ion concentration and/or with ions having lower valence numbers. Such membranes and gels can be used advantageously during recovery from surgery to ligaments and 15 tendons, tissues which characteristically heal slowly. Thus, a long-lasting composition could minimize the formation of adhesions between those tissues.

III. Incorporation of Drugs into Compositions

20 Ionically cross-linked and non-ionically cross-linked gels and membranes can be made which incorporate drugs to be delivered to the surgical site. Incorporation of drugs into membranes is described in Schiraldi et al., U.S. Patent No. 4,713,243 and in U.S. Patent 5,906,997, incorporated herein fully by reference.. The incorporation of drugs into the compositions may be at either the manufacturing stage or added later but prior to insertion. Drugs which may inhibit 25 adhesion formation include antithrombogenic agents such as heparin or tissue plasminogen activator, drugs which are anti-inflammatory, such as aspirin, ibuprofen, ketoprofen, or other, non-steroidal anti-inflammatory drugs. Furthermore, hormones, cytokines, osteogenic factors, chemotactic factors, proteins

and peptides that contain an arginine-glycine-aspartate ("RGD") motif, analgesics or anesthetics may be added to the compositions, either during manufacture or during conditioning. Any drug or other agent which is compatible with the compositions and methods of manufacture may be used with the present invention.

5 Desirably, to increase hemostatic properties of gels and foams, hemostatic agents, including vasoconstrictors, fibrillar collagen and clotting factors such as thrombin can be added. Vasoconstrictors can include adrenergic agonists, for example, norepinephrine, epinephrine, phenylpropanolamine, dopamine, metaraminol, methoxamine, ephedrine, and propylhexedrine.

10

IV. Uses of PA/PO Compositions

The types of surgery in which the gel and/or foam compositions of the instant invention may be used is not limited. Examples of surgical procedures are 15 described in U.S. Patent Nos: 5,906,997, 6,017,3401, and 6,034,140 as well as U.S. Patent Application No: 09/472,110, filed December 27, 1999, each patent and application incorporated herein fully by reference. Additionally, wound healing can be augmented for a variety of wounds, including abdominal injury, muscular injuries, skin injuries, and other soft-tissue injuries. Moreover, in certain 20 embodiments, the gels of this invention can be placed at a desired site using an endoscope. Such types of administration can include laparoscopy, endoscopy and injection through needles.

25

V. Polyacid/Polyalkylene Oxide Foams and Delivery Systems for Gels and Foams

In other embodiments of this invention, foams of polyacids and polyalkylene oxides are provided. Foams offer advantages over gels in that they can require less material, the material can be less dense, and therefore can be

5 applied more easily against a gravity gradient, i.e., uphill, and can adhere more evenly to a tissue without flowing or sliding off. To make PA/PO foams, typically a mixture of PA/PO gel is exposed to increased pressure in the presence of a charging gas, including but not limited to CO₂, N₂, a noble gas such as helium, neon, argon, or any other gas that is relatively inert physiologically and does not adversely affect the polyacid or polyalkylene oxide or other components of the mixture.

10 The gel material can be loaded into a pressurized canister, such as those used for aerosol applications. Upon releasing the pressure, such as by opening the valve, the pressure in the canister forces some of the gas/gel mixture out of the canister, thereby relieving the pressure on the gel. Some gas dissolved in the gel comes out of solution and can form bubbles in the gel, thereby forming the foam. The foam then expands until the gas pressure within the foam reaches equilibrium with the ambient pressure. In some embodiments, the bubbles can coalesce and 15 can ultimately disperse, leaving the mixture in a gel-like state, adhering to the tissue.

20 In certain other embodiments, it can be desirable to include a surface-active agent in the mixture to prolong the time that the foam remains in the foamy state. Any surfactant can be used that is biocompatible and does not adversely affect the materials in the foam.

25 Delivery systems for gels and foams are further described in the concurrently filed Utility Patent Application titled "Polyacid/Polyalkylene Foams and Gels and Methods for Their Delivery" Mark E. Miller, Stephanie M. Cortese, Herbert E. Schwartz and William G. Oppelt, inventors. The above patent application is herein incorporated by reference in its entirety.

In general, delivery systems for gels comprise the composition to be delivered, a pressurized container and a valve. The composition is loaded into the canister under pressure, and when a valve is opened, the composition flows out of

the canister under pressure. In certain embodiments, hemostatic antithrombogenic compositions can be delivered to a surgical site using such delivery systems.

The hemostatic compositions can also be used in sponge form. Manufacture of sponges is described in U.S. Patent Application No: 09/472,110, 5 incorporated herein fully by reference.

VI. Examples

In the following examples, PA/PO gel compositions are described for CMC as an exemplary carboxypolysaccharide, and PEO is the exemplary polyalkylene oxide. It is understood that association complexes of other carboxypolysaccharides, other polyacids, polyethers and other polyalkylene oxides can be made and used in similar ways. Thus, the invention is not limited to these Examples, but can be practiced in any equivalent fashion without departing from the invention.

15

Example 1: Antithrombogenic effect of CMC/PEO Membranes I

Samples of CMC (7 HF PH) and CMC/PEO (5000 kd) membranes were made with CMC/PEO ratios of 80%/20%, 65%/35%, and 50%/50% at a pH of 20 from 2.7 to 2.9. An observation chamber for adherent platelets was assembled consisting of a polymer-coated glass slide, two polyethylene spacers, and a glass coverslip. Human blood, obtained from healthy adult volunteers after informed consent, was collected in heparin-containing evacuated containers (Vacutainers™, Becton-Dickinson, Rutherford, NJ). Heparinized blood was centrifuged at 100g 25 for 10 min to obtain platelet-rich plasma (PRP).

Two hundred microliters ("μL") of PRP was instilled into the platelet observation chamber. Platelets in PRP were allowed to adhere and activate on the polymer surfaces for 1 hr at room temperature. Non-adherent platelets and plasma proteins were removed by washing the chamber with PBS. Adherent platelets were

fixed with 2.0% (w/v) glutaraldehyde solution in PBS for 1 hour. After washing with PBS, the platelets were stained with 0.1% (w/v) Coomassie Brilliant Blue (Bio-Rad, Hercules, CA) dye solution for 1.5 hours. Stained platelets were observed using a Nikon Labophot™ II light microscope at 40X magnification
5 (Melville NY). The image of adherent platelets was transferred to a Sony Trinitron™ video display using a Mamamatsu CCD™ camera (Mamamatsu-City, Japan). The Hamamatsu Argus-10™ image processor was used to calculate the number of platelets per 25,000 μm^2 surface area in every field of observation. The extent of platelet activation was determined qualitatively from the spreading
10 behavior of adherent platelets. Images of activated platelets were obtained from the Sony Trinitron™ video display screen using a Polaroid ScreenShooter™ camera (Cambridge, MA).

The number of adherent platelets and the extent of platelet activation are considered early indicators of the thrombogenicity of blood-contacting
15 biomaterials. Platelet activation was measured qualitatively by the extent of platelet spreading on the polymer surfaces. The extent of platelet spreading was judged from 1 (least reactive) to 5 (most reactive) as described in Table 1, which is based on the criteria of Lin et al., Polyethylene surface sulfonation. Surface characterization and platelet adhesion studies. *J. Coll. Interface Sci.* **164**: 99-106
20 (1994), incorporated herein fully by reference.

Table 1
Evaluation of Platelet Activation: Surface-Induced Spreading

5	Platelet Activation Stage	Approximate Spread Area (μm^2)	Remarks
	1	10 - 15	Contact-adherence. Platelets not active.
	2	15 - 25	Partially active. Initiation of pseudopods.
	3	25 - 35	Partially activated. Pseudopod extension and initiation of release of granular contents.
10	4	35 - 45	Partially activated. Significant pseudopod formation and extension. Complete release of granular contents.
	5	> 45	Fully activated. Retraction of pseudopods leading to the flat or "pancake" shape.

Table 2
Platelet Adherence And Activation By CMC/PEO Membranes

15	Membrane Composition	Number of Adherent Platelets (per 25,000 μm^2) ^a	Extent of Activation (μm^2)
	100% CMC	95.8 ± 15.3	2.96 ± 0.37
	80% CMC/20% PEO	48.1 ± 10.9	3.25 ± 0.35
	65% CMC/35% PEO	17.8 ± 4.25	1.57 ± 0.39
20	50% CMC/50% PEO	5.25 ± 2.67	1.00 ± 0.00

a: mean \pm standard deviation (n=24).

25

Table 2 shows that significant number of platelets had adhered and activated on membranes made of 100% CMC. On the average, more than 95 activated platelets were present per 25,000 μm^2 . The number of adherent platelets and the extent of activation decreased with increasing PEO content in the membranes. The membranes having a CMC/PEO ration of 50%/50% had the least

number of platelets. On the average, only 5 contact-adherent platelets were present on these membranes.

The results of this study indicate that CMC/PEO membranes, especially the 50%/50% CMC/PEO membrane, is highly anti-thrombogenic, based on the 5 reduction in the number of adherent platelets and the extent of platelet activation on these surfaces. Thus, increasing the amount of PEO in membranes increases their antithrombogenic properties.

10 **Example 2: Blood Prothrombin Time after Spinal Injection of CMC/PEO Mixtures**

To determine whether CMC and PEO adversely affect blood clotting *in vivo*, we performed a series of studies in which we injected CMC/PEO mixtures into the spines of rabbits, and measured prothrombin time in blood drawn from the animals.

15 Four rabbits (2.4 to 2.8 kg) were anesthetized using ketamine (40 mg/kg) and xylazine (8 mg/kg), and 0.20 ml of clinical grade 2% CMC, 0.05% PEO, 50% H₂O and 47.9% balanced salt solution (Lot #SD011089) was injected into the lower spinal area using a 27-gauge, ½ inch needle. A fifth, uninjected rabbit (2.8 kg) served as the control. Blood samples (approximately 1.6 ml) were taken at 0
20 (before injection), 2, 6, 24, 48, and 96 hr post dose. To 1.6 ml of the collected blood, 0.2 ml of 3.8% sodium citrate solution was added. After mixing plasma was prepared by centrifuging the sample at 2000 rpm for 3 to 5 minutes in a clinical centrifuge. Plasma was pipetted into a separate labeled tube and kept on ice. The sample was frozen and sent to California Veterinary Diagnostics, Inc., West
25 Sacramento, CA for prothrombin-time determination, which was conducted in compliance with FDA's Good Laboratory Practice Regulations.

Table 3 shows the prothrombin times for each sample of rabbit plasma at various sampling times. Rabbit blood coagulates more quickly than human blood

(Didisheim et al., *J. Lab. Clin. Med.* 53, 866-1959); thus, several of the samples collected from these rabbits coagulated before analysis. However, the samples assayed showed no effect of the CMC/PEO mixture on the prothrombin time except for rabbit No. 3, which showed a transient increase but recovered by day 4.

5 We conclude that dural application of CMC/PEO mixtures do not adversely affect whole blood prothrombin time.

10 **Table 3**
Prothrombin Time (Seconds) of Rabbits Injected with CMC/PEO

	Rabbit Number				
Time (hr)	1	2	3	4	5*
15	0	7.2	7.2	7.1	8.4
	2	-	7.1	7.1	7.1
	6	7.3	7.1	7.1	7.8
	24	7.2	7.1	10.6	7.1
	48	7.3	-	10.3	-
	96	6.2	6.5	6.5	6.0

20 *Control rabbit not injected with CMC/PEO.
- indicates that assay was not performed because the sample had coagulated.

25 **Example 3:** Surface and Blood-Contacting Properties of CMC/PEO Films
Introduction:

30 The purpose of this study was to determine whether the CMC/PEO membranes of this invention have anti-thrombogenic properties. CMC (700 kd) and PEO (4400 kd) were blended and the mixture was cast into thin films at a pH of 4.2. The bilayered films had approximately the same thickness as the monolayered films. Also, for the bilayered films, the different layers had about the

same mass. The films were evaluated for surface and blood compatibility properties.

A. Platelet Adhesion and Activation II:

5 Introduction

Platelet adhesion and activation is an important indicator of blood-biomaterial interactions (Hoffman. *Blood-Biomaterial Interactions: An Overview*. In S.L. Copper and N.A. Peppas (eds). *Biomaterials: Interfacial Phenomena and Applications*. Volume 199. American Chemical Society, Washington, DC. 1982 10 pp 3-8, incorporated herein fully by reference). The initial number of adherent platelets and the extent of platelet activation on biomaterial surface correlates with the potential long-term blood-compatibility profile (Baier et al. *Human Platelet Spreading on Substrata of Known Surface Chemistry*. J. Biomed. Mater. Res. 19: 1157-1167 (1985), incorporated herein fully by reference). When in contact with 15 polymeric surfaces, platelets initially retain their discoid shape present in the resting state and the spread area is typically between 10 - 15 μm^2 . Upon activation, platelets extend their pseudopods and initiate the release of granular contents. During the partial activation stage, the area of the spread platelet can increase to about 35 μm^2 . When the platelets are fully-activated, they retract the pseudopods 20 to form circular or "pancake" shape and the spread area increases to 45 or 50 μm^2 (Park et al. *Morphological Characterization of Surface-Induced Platelet Activation*. Biomaterials 11: 24-31 (1990), incorporated herein fully by reference). The spreading profiles of activated platelets were used to create five activation stages as described by Lin et al. (Lin et al. *Polyethylene Surface Sulfonation: 25 Surface Characterization and Platelet Adhesion Studies*. J. Coll. Interface. Sci. 164: 99-106 (1994), incorporated herein fully by reference). Clean glass promotes platelet adhesion and activation (Park et al. *The Minimum Surface Fibrinogen Concentration Necessary for Platelet Activation on Dimethyldichlorosilane-Coated*

Glass. J. Biomed. Mater. Res. 25: 407-420 (1991), incorporated herein fully by reference).

Methods

5 Platelet adhesion and activation measurement was performed as previously described (M. Amiji, *Permeability and Blood Compatibility Properties of Chitosan-Poly(ethylene oxide) Blend Membranes for Hemodialysis. Biomaterials 16:* 593-599 (1995), M. Amiji. *Surface Modification of Chitosan Membranes by Complexation-Interpenetration of Anionic Polysaccharides for Improved Blood*

10 *Compatibility in Hemodialysis. J. Biomat. Sci., Polym. Edn. 8:* 281-298 (1996), both articles incorporated herein fully by reference). Briefly, a platelet observation chamber was assembled consisting of film-covered clean glass slide, two polyethylene spacers, and a glass coverslip. Human blood, obtained from healthy adult volunteers after informed consent, was collected in heparin-containing

15 evacuated containers (Vacutainers®, Becton-Dickinson, Rutherford, NJ). Heparinized blood was centrifuged at 100g for 10 minutes to obtain platelet-rich plasma (PRP).

The polymer compositions studied included a non-irradiated film A having side 1 composed of 95% CMC and 5% PEO, and side 2 composed of 60 % CMC

20 and 40% PEO. Film B was otherwise identical to Film A, except that the film had been irradiated with γ -radiation as described in U.S. Application No: 09/472,110, incorporated herein fully by reference. Films C and D were made of 77.5% CMC and 22.5 % PEO and film C was not irradiated, whereas film D was irradiated. Film E was 100% CMC and was irradiated.

25 To measure platelet adherence and activation, two-hundred (200) μ L of PRP was instilled into the platelet observation chamber. Platelets in PRP were allowed to adhere and activate on the polymer surfaces for one hour at room temperature. Non-adherent platelets and plasma proteins were removed by

washing the chamber with phosphate-buffered saline (PBS, pH 7.4). Adherent platelets were fixed with 2.0% (w/v) glutaraldehyde solution in PBS for 1 h. After washing with PBS, the platelets were stained with 0.1% (w/v) Coomassie Brilliant Blue (Bio-Rad, Hercules, CA) dye solution for 1.5 h. Stained platelets were 5 observed using a Nikon Labophot® II (Melville, NY) light microscope at 40X magnification. The image of adherent platelets was transferred to a Sony Trinitron® video display using a Hamamatsu CCD® camera (Hamamatsu-City, Japan). The Hamamatsu Argus-10® image processor was used to calculate the 10 number of platelets per 25,000 μm^2 surface area in every field of observation. The data indicates average number of adherent platelets \pm S.D. from at least twelve fields of observation and two independent experiments.

The extent of platelet activation was determined qualitatively from the spreading behavior of adherent platelets as described above in Table 4.

15

Results:

The extent of platelet adhesion was determined by counting the number of platelets per 25,000 μm^2 surface area. Surface-induced platelet activation was measured qualitatively from the spreading behavior of adherent platelets as shown in Table 4.

20

Table 4
Platelet Adherence and
Activation by Control and CMC/PEO Films^a

5	Film	Number of Platelets (per 25,000 μm^2)	Extent of Activation (μm^2)
	Glass	157.3 ± 19.6^b	4.8 ± 0.3
	A, side 1	26.0 ± 5.4	2.2 ± 0.1
	A, side 2	6.2 ± 2.2	1.2 ± 0.4
	B, side 1	27.9 ± 7.3	2.4 ± 0.3
10	B, side 2	6.0 ± 2.9	1.2 ± 0.1
	C	3.5 ± 1.7	1.0 ± 0.0
	D	3.4 ± 1.1	1.0 ± 0.0
	E	62.8 ± 12.4	3.6 ± 0.4

15 As shown in Table 4, platelets adhered to the glass surface and became activated. Platelets did not adhere in as great a number to CMC/PEO membranes, however, and were not activated to the same degree as by glass. The degree of adherence and activation was inversely related to the PEO concentration. Thus, increasing the amount of PEO decreased both platelet adherence and platelet activation. Moreover, comparing films A and C (radiated) with films B and D (non-radiated) there was no effect of gamma radiation on platelet adhesion and activation.

20 From the platelet adhesion and activation studies, increased surface PEO correlated with reduced adherence and activation of platelets. Based on these 25 observations, CMC-PEO membranes with high PEO content are relatively non-thrombogenic.

B. Plasma Recalcification Time:

Introduction

Plasma recalcification time measures the length of time required for fibrin clot formation in calcium-containing citrated plasma that is in contact with the 5 surface of interest. It is a useful marker of the intrinsic coagulation reaction. Plasma recalcification time is a measure of the intrinsic coagulation mechanism (Renaud, The recalcification plasma clotting time. A valuable general clotting test in man and rats. *Can. J. Physiol. Pharmacol.* **47**: 689-693 (1969), incorporated herein fully by reference). Since the time required for contact activation of plasma 10 varies with the type of surface, the plasma recalcification time is used as an indicator of blood compatibility of biomaterials (Rhodes et al., Plasma recalcification as a measure of the contact phase activation and heparinization efficacy after contact with biomaterials. *Biomaterials* **15**: 35-37 (1994), incorporated herein fully by reference).

15

Methods

Human blood was collected in evacuated containers (Vacutainers, Becton-Dickinson) in the presence of sodium citrate buffer as an anticoagulant. Citrated blood was centrifuged at 2,500g for 20 minutes to obtain platelet-poor plasma. A 20 round sections (20 mm in diameter) of the control and CMC-PEO films were cut with an aid of a sharp scalpel. Tissue Culture Polystyrene (TCP) surfaces are created by treating polystyrene microplates with oxygen plasma to convert the hydrophobic surface into a hydrophilic one. The film sections were placed in 12-well tissue-culture polystyrene (TCP, Falcon®, Becton-Dickinson) microplates and 25 hydrated with 2.0 ml of PBS for 10 minutes. Excess PBS was removed by suction.

The compositions tested were the same as described above for platelet adhesion and activation. Film A had side 1 composed of 95% CMC and 5% PEO, and side 2 composed of 60 % CMC and 40% PEO. Film B was otherwise identical

to Film A, except that the film had been irradiated with γ -radiation as described in U.S. Application No: 09/472,110, incorporated herein fully by reference. Films C and D were made of 77.5% CMC and 22.5 % PEO and film C was not irradiated, whereas film D was irradiated. Film E was 100% CMC and was irradiated.

5 Plasma recalcification time of citrated plasma in contact with control and CMC-PEO blend films was measured according to the procedure described by Brown (Brown; *Hematology: Principles and Procedures*. Sixth Edition. Lea and Febioger, Philadelphia, PA. 1993, pp. 218, incorporated herein fully by reference). Briefly, 1.0 ml of citrated plasma was mixed with 0.5 ml of 0.05 M calcium 10 chloride and incubated with hydrated film samples in a water-bath at 30° C. The samples were occasionally removed from the water-bath and gently stirred. The time required for fibrin clot formation was recorded. The data indicates average of the plasma recalcification time \pm S.D. from four independent experiments. Plasma recalcification time was determined using the methods of Renaud and 15 Rhodes et al., cited above. The results of this study are presented in Table 5.

Table 5
Recalcification Time for Plasma in Contact with Control and
CMC-PEO Films^a

5	Film	Plasma Recalcification Time (minutes)
	Control TCP ^b	6.3 \pm 0.2 ^c
	A, side 1	13.9 \pm 0.6
	A, side 2	17.8 \pm 0.5
10	B, side 1	13.5 \pm 0.9
	B, side 2	17.8 \pm 0.6
	C	15.3 \pm 0.8
	D	15.1 \pm 0.5
	E	5.6 \pm 0.3

15 ^a The time required for fibrin clot formation with calcium-containing citrated human plasma was measured in minutes.

^b Tissue-culture polystyrene (TCP) 12-well microplate was used as a control.

^c Mean \pm S.D. (n=4).

20 The contact activation time on TCP was about 6.3 minutes, and on 100% CMC (film E) was about 5.6 minutes. This is similar to the contact activation time previously found for clean glass surfaces. In contrast, the plasma recalcification times on PEO-containing films (samples A-D) were significantly higher than the control TCP or CMC surfaces. The recalcification time correlated with the 25 increased PEO content of the film, with increased PEO resulting in increased recalcification time. Therefore, contact activation of plasma was substantially reduced for membranes with increased amounts of PEO.

Conclusions:

Films containing increased amounts of PEO on their surfaces are anti-thrombogenic and can prevent formation of fibrin clots from forming on the surfaces of the films. The antithrombogenic effects are dependent on the amount 5 of PEO. Thus, manufacturing films having increased PEO concentration can decrease thrombogenicity.

Example 4: Hemostatic Effects of CMC/PEO Membranes

The purpose of these studies is to determine the hemostatic properties of 10 CMC/PEO polymer preparations. These studies were carried out at Livingston Research Institute under the direction of the inventors.

Introduction

Examples 1-3 above demonstrate some effects of CMC/PEO membranes 15 to inhibit thrombogenesis, that is, the adherence and activation of platelets in blood. However, antithrombogenicity and hemostasis are not the same phenomena. Antithrombogenicity is a property of a surface to inhibit the adherence and/or activation of platelets on that surface. Hemostasis is a complex set of physiological events within blood vessels that ultimately can result in the cessation of blood flow 20 due to hemorrhage. According to a possible mechanism of hemostasis, within seconds of a vascular trauma, platelets adhere to the subendothelial collagen exposed by the trauma. Once a monolayer of platelets is formed, mediators can be released from the adherent platelets, and those mediators can recruit additional platelets to aggregate upon the adherent platelets. This process can continue until 25 a platelet "plug" is formed. The platelet plug can be stabilized by a fibrin network formed as a result of activation of the coagulation cascade. The platelet/fibrin plug can grow in size until the lumen of the hemorrhaging blood vessel is occluded and blood flow stops. Thus, an antithrombogenic property of a composition is not

necessarily inconsistent with the hemostatic property of the composition. Hemostasis can also be promoted by constriction, or narrowing, of the local blood vessels.

5 Methods:

Animals: Twenty-three (23) New Zealand White rabbits, 2.4 - 2.7 kg each, were purchased from Irish Farms (Norco, CA) and quarantined in the University of Southern California ("USC") vivarium for at least 2 days prior to use. Three rabbits were used for preliminary experiments. Twenty rabbits were divided into 10 five treatment groups of four animals each, prior to initiation of surgery. The animals were housed with a light:dark cycle of 12 hrs:12 hrs, were fed *ad libitum*.

15 Animals were anesthetized using ketamine (55 mg/kg)/xylazine (5 mg/kg), intramuscularly. The abdominal area was shaved and prepared for sterile surgery with Betadine and alcohol solution. A midline laparotomy was performed

Materials: The CMC/PEO polymer gels used had a total solids content of 2% in distilled water, the solids being 90% CMC (7HF, Hercules) and 10 % PEO (4.4 Md molecular weight). Gels were made according to methods in the U.S. 20 Patent Application No: 09/472,110, filed December 27, 1999. For membrane studies, membranes were 77.5 % CMC (7HF)/22.5 % PEO (4.4 Md) at a pH of either 3.0 ("SPF 3.0") or 4.0 ("SPF 4.0"), made according to methods described in U.S. Application No: 09/472,110, filed December 27, 1999. When dried, the membranes had thicknesses of between about 0.0022" and about 0.0028".

Splenic Injury

A 4 x 4 inch gauze sponge was used to isolate the spleen. A lacerating apparatus was made by clamping a No. 15 scalpel blade in a straight hemostat so that 2 mm of the cutting edge projected from the side of the hemostat. A uniform 5 laceration was made by pulling the blade along the greater curvature of the spleen, beginning about 1 mm from the upper pole and ending about 1 mm from the lower pole.

Hepatic Injury

10 The liver was exteriorized from the abdomen and gently laid on a gauze sponge. Hepatic injury was made using a metal template. A liver wound was made by pressing a metal template on the surface of the exteriorized liver and excising the protruding tissue with a sharp blade. The injured area was 3 cm².

15 Application of Hemostatic CMC/PEO Compositions

After injury, the affected organ was treated by applying the hemostatic composition to the site. For the liver injuries, the hemostatic material was applied and gentle pressure was applied. Observations were made over an 18 minute period, and the total time, in minutes, required to achieve complete hemostasis was 20 measured.

Preliminary Studies

Three rabbits were used for preliminary studies. One animal received a splenic injury, one animal received a hepatic injury and one animal received both 25 splenic and hepatic injuries. In the one animal in which both injuries were made, we found that one injury made it difficult to interpret the results of hemostasis at the other site. Thus, for the further experiments, we made only hepatic injuries to the animals.

Results

The effects of CMC/PEO compositions on bleeding time (in minutes) are shown in Table 6.

5

Table 6
Effects of CMC/PEO Gels and Membranes on Bleeding Time in Rabbits^a

10

Animal No:	1	2	3	4	Mean	SEM
Control	> 18	9.75	11.0	> 18	14.18	1.92
Gelfoam™	9.08	6.25	2.83	3.0	5.28	1.29
SPF-3	1.50	2.75	1.17	1.33	1.68	0.31
SPF-4	2.50	3.83	3.0	2.53	2.97	0.27
SPG	2.75	4.67	4.0	6.08	4.33	0.60

a: Data expressed as mean \pm standard error of the mean (SEM).

15

The results show that the control animals had a long bleeding time (over 14 minutes). Each of the treated animals had decreased bleeding time. Unexpectedly, the animals receiving the membranes having a pH of 3 had the shortest bleeding time, being less than about 0.1 of the time of the control animals. The membrane having a pH of 4 was also effective, requiring about 1/5 the time to achieve hemostasis. The gel-treated animals showed a bleeding time of 4.33 minutes, which represents a decrease of about 70% compared to untreated control animals, and about 20 % compared to Gelfoam™-treated animals. Animals treated with Gelfoam™ also had reduced bleeding time compared to untreated control animals. In general, it appears that the membrane embodiments of this invention have slightly greater hemostatic properties than Gelfoam™, with bleeding times being about 1/3 and 2/3, respectively, for pH 3 and pH 4, of the bleeding time observed with Gelfoam™.

20

25

It can be appreciated that with reduced pH, the acid load delivered to tissues can be increased compared to compositions having higher pH. In certain embodiments of hemostatic membranes, the membranes can be made thin. For example for acidic membranes having the same surface area and pH, a membrane 5 having only one-half the thickness will deliver only about one-half the acid load to the tissue. Thus, by making acidic membranes very thin, the desired hemostatic property can be achieved while minimizing adverse effects of delivering a high acid load to the animal and tissue.

10 **Example 5: Polyacid/Polyalkylene Oxide Foams**

In addition to the membranes and gels described other embodiments of this invention include foams. Foams of PA/PO mixtures can be made by dissolving a gas, such as CO₂ or N₂ in the mixture under more than atmospheric pressure. The gas and mixture is allowed to equilibrate so that the partial pressure of the gas in 15 the mixture is about the same as the partial pressure of the gas in the gas phase. Any device can be used to deliver foams comprising the compositions of this invention. It can be desired to use a delivery system as described in the concurrently filed U.S. Utility Patent Application titled: "Polyacid/Polyether Foams and Gels and Methods for Their Delivery" Mark E. Miller, Stephanie M. Cortese, 20 Herbert E. Schwartz and William G. Oppelt, inventors, filed concurrently. This patent application is incorporated herein fully by reference.

Example 6: Hemostatic Comparison of CMC/PEO Gels

The purpose of this study was to evaluate the ability of CMC/PEO gels to 25 perform as hemostatic agents in a common animal model of profuse hepatic bleeding. The study was performed under the inventors' direction at Covance Research Laboratories.

Introduction

Hemostatic evaluation of CMC/PEO gels and film formulations of this invention and a prior art product (Gelfoam™) was carried out in an animal model of profuse bleeding at Livingston Research Institute. This study indicated that 5 each of the gel and film formulations tested were successful in reducing the bleeding time.

In another study, CMC/PEO gel formulations exhibited hemostatic properties in a Lee-White blood clotting model. This in vitro method tested the ability of gel formulations, with and without added thrombin, to clot human blood. 10 We compared the CMC/PEO preparations with Proceed™ (Fusion Medical). This study showed substantially decreased clotting time compared to controls. Gel preparations of this invention with thrombin showed an even greater decrease in clotting time as compared to the controls, and was comparable to the clotting time observed for Proceed™.

15

Materials

Two types of CMC/PEO gels were used in this study. Both were composed of 90% CMC 10% PEO (dry weight percentages). The CMC was 7HF from Hercules and the PEO had a 4.4 Md molecular weight from RITA). However, Gel 20 A was made with 3.1 % total solids content, whereas Gel B had 3.4 % total solids content. The gels were made according to methods disclosed in U.S. Patent Application Serial No: 09/472,110, filed December 27, 1999, incorporated herein fully by reference.

Dry CMC and PEO were mixed before being added to a vortexing solution 25 of deionized water (1500 ml), calcium chloride and sodium chloride. Once the dry chemicals were completely incorporated into the solution, the speed of vortexing was reduced and the gel was allowed to mix for approximately two hours to

achieve homogeneity. The gel was then filtered into syringes and sterilized in a steam autoclave.

The osmolality was then adjusted to a physiologically acceptable value of about 300 mmol/kg by adding about 13 ml of a 30% w/v solution of NaCl and 5 further mixing the gel. The calcium ion-associated gels did not require any pH adjustment after their manufacture. The gel was then sterilized in an autoclave for 15 minutes at 250° C.

Methods

10 One adult pig was anesthetized. The domestic pig was used because its liver is sufficiently large to accommodate the required number of test sites. Following preparation for surgery, a midline incision was made to perform a laparotomy. The liver was exposed and surface defects were created using a template to guide in the preparation of a 1 cm x 1 cm surface defect to create 15 profuse bleeding. The template was pressed onto the surface of the liver and the protruding tissue was first scored along the perimeter with a scalpel blade, pulled up on the center with tweezers, and then cut underneath to remove the one square cm flap so produced.

Once the injury was made, the injury site was patted with gauze to remove 20 excess blood, the gel product was then applied, and tamponade was immediately applied using gauze for one minute. Control sites received the standard one minute tamponade without any gel preparation. After one minute, the injury site was observed to see if bleeding had stopped. If bleeding had stopped, the time was recorded, and if not, the site was allowed to complete its clotting cycle without 25 additional tamponade. In cases where bleeding was still very active at the one-minute time point, tamponade was applied at one-minute intervals. The recorded “clotting time” recorded was the time from the removal of the 1 cm x 1 cm flap of

liver until the blood completely clotted. A standard volume (0.5 ml) of test gel was applied to each site followed by tamponade as described.

The total number of sites so created in one animal did not exceed 35 sites. There were 7 sites for each test material and 7 control sites available. As bleeding 5 at each site stopped, another site was prepared and used to measure hemostasis with another gel sample.

Results

The results follow in Table 7 and illustrate the hemostatic capability of the 10 CMC/PEO gels of this invention compared with that of Proceed™.

Table 7
Effect of CMC/PEO Gels on Bleeding Time in Pig Hepatic Model

Test Article	Clotting Time (min)	Average	Standard Deviation
Gel A + thrombin	1.35	1.65	0.30
	1.50		
	1.72		
	2.03		
Gel B + thrombin	1.55	1.59	0.28
	1.42		
	1.45		
	2.08		
Gel B alone	1.43		
	9.23	10.38	2.75
	15.0		
	10.0		
Proceed™	7.68		
	10.0		
	2.05	1.49	0.42
	1.53		
Blood only	1.08		
	1.28		
	8.37	9.12	1.03
	10.0		
25	8.10		
	10.0		

Conclusion

The results of the above studies demonstrated that the thrombin-containing CMC/PEO gels of this invention are effective hemostatic agents. On average, gels of this invention having thrombin decreased clotting time to about 15% of the sites 5 treated with gel without thrombin. Moreover, the gel having higher total solids content (Gel B) had a slightly better hemostatic effect than the gel (Gel A) having lower total solids content. Additionally, Gel B decreased clotting time to about 17% of the time needed for those sites not exposed to any hemostatic agent (untreated controls).

10

Other features, aspects and objects of the invention can be obtained from a review of the figures and the claims. All citations herein are incorporated by reference in their entirety. It is to be understood that other embodiments of the invention can be developed and fall within the spirit and scope of the invention and 15 claims.

We Claim:

1. A composition comprising an association complex of a polyacid (PA) and a polyalkylene oxide (PO), which is hemostatic and possesses at least one 5 additional property selected from the group consisting of antiadhesion, bioadhesiveness, antithrombogenicity and bioresorbability, and wherein the pH of said composition is below about 7.5.
2. The composition of claim 1, wherein said polyacid is selected from the 10 group consisting of a carboxypolysaccharide, polyacrylic acid, polyamino acid, polylactic acid, polyglycolic acid, polymethacrylic acid, polyterephthalic acid, polyhydroxybutyric acid, polyphosphoric acid, polystyrenesulfonic acid, and copolymers of said polyacids.
- 15 3. The composition of claim 1, wherein the polyacid is a carboxypolysaccharide selected from the group consisting of carboxymethyl cellulose (CMC), carboxyethyl cellulose, chitin, carboxymethyl chitin, hyaluronic acid, alginate, propylene glycol alginate, pectin, carboxymethyl dextran, carboxymethyl chitosan, heparin, heparin sulfate, chondroitin sulfate and 20 polyuronic acids including polymannuronic acid, polyglucuronic acid and polyguluronic acid..
- 25 4. The composition of claim 1, wherein the polyacid is carboxymethylcellulose.
5. The composition of claim 1, wherein the polyacid is carboxymethylcellulose having a molecular weight in the range of about 10 kd to

about 10,000 kd and a degree of substitution in the range of greater than about 0 to about 3.

6. The composition of claim 1, wherein said polyalkylene oxide is selected
5 from the group consisting of polypropylene oxide, polyethylene glycol,
polyethylene oxide, and PEO/PPO block copolymers.

7. The composition of claim 1, wherein said polyalkylene oxide is
polyethylene oxide or polyethylene glycol having a molecular weight in the range
10 of about 200 d to about 8000 kd.

8. The composition of claim 1, wherein said polyalkylene oxide is
polyethylene glycol having a molecular weight in the range of about 200 Daltons
to about 5000 Daltons.

15 9. The composition of claim 1, wherein said PA is in the range of about 10 %
to about 99 % by weight, of the total solids content.

10. The composition of claim 1, wherein the PA is in the range of about 50 %
20 by weight to about 99 % by weight, of the total solids content.

11. The composition of claim 1, wherein the PA is in the range of about 90 %
by weight to about 99 % by weight, of the total solids content.

25 12. The composition of claim 1, wherein the PO is in the range of about 1 %
by weight to about 90 % by weight, of the total solids content.

13. The composition of claim 1, wherein the PO is in the range of about 1 % by weight to about 10 % by weight, of the total solids content.
14. The composition of claim 1, wherein the PO is about 2.5 % by weight, of 5 the total solids content.
15. The composition of claim 1, wherein the total solids content of the gel is in the range of about 1 % to about 10 %.
- 10 16. The composition of claim 1, further comprising a trivalent cation.
17. The composition of claim 16, wherein said cation is selected from the group consisting of Fe^{+3} , Al^{+3} , and Cr^{+3} .
- 15 18. The composition of claim 1, further comprising a divalent cation.
19. The composition of claim 18, wherein said cation is a divalent cation selected from the group consisting of Ca^{+2} , Zn^{+2} , Mg^{+2} and Mn^{+2} .
- 20 20. The composition of claim 1, wherein the pH of the gel is in the range of about 2.0 to about 7.5.
21. The composition of claim 1, wherein the pH of the gel is in the range of about 2.5 to about 6.0.
- 25 22. The composition of claim 1, further comprising a drug.

23. The composition of claim 1, further comprising a drug selected from the group consisting of antithrombogenic drugs, hemostatic agents, anti-inflammatory drugs, hormones, chemotactic factors, analgesics, growth factors, cytokines, osteogenic factors and anesthetics.

5

24. The composition of claim 1, further comprising a drug selected from the group consisting of heparin, tissue plasminogen activator, thrombin, aspirin, ibuprofen, ketoprofen, proteins and peptides containing an RGD motif, and non-steroidal anti-inflammatory drugs.

10

25. The composition of claim 1 having a viscosity below about 500,000 centipoise.

15

26. The composition of claim 1, wherein said composition is dried to form a membrane.

20

27. A method for manufacturing a hemostatic composition, comprising the steps of:

- (a) selecting a polyacid;
- (b) selecting a polyalkylene oxide;
- (c) forming a solution of said polyacid and said polyalkylene oxide; and
- (d) adjusting the pH of said composition to the range of below about

7.5.

25 28. The method of claim 27, further comprising the step of adding a hemostatic agent.

29. The method of claim 28, wherein said hemostatic agent is thrombin.

30. The method of claim 27, wherein the polyacid is selected from the group consisting of a carboxypolysaccharide, polyacrylic acids, polyamino acids, polylactic acid, polyglycolic acid, polymethacrylic acid, polyterephthalic acid, polyhydroxybutyric acid, polyphosphoric acid, polystyrenesulfonic acid, and 5 copolymers of said polyacids.

31. The method of claim 27, wherein the polyacid is a carboxypolysaccharide selected from the group consisting of carboxymethyl cellulose (CMC), carboxyethyl cellulose, chitin, carboxymethyl chitin, hyaluronic acid, alginate, 10 pectin, carboxymethyl dextran, carboxymethyl chitosan, heparin, heparin sulfate, chondroitin sulfate polyuronic acids including polymannuronic acid, polyglucuronic acid and polyguluronic acid..

32. The method of claim 27, wherein said polyalkylene oxide is selected from 15 the group consisting of polypropylene oxide, polyethylene glycol, polyethylene oxide and copolymers of said polyalkylene oxides.

33. The method of claim 27, further comprising adjusting the pH in the range of about 3.5 to about 7.5.

20

34. The method of claim 27, wherein said multivalent cation is Ca^{++} .

35. The method of claim 27, further comprising the step of sterilizing the composition.

25

36. A method for providing hemostasis comprising the step of placing the composition of claim 1 in contact with a bleeding tissue.

37. A method for providing hemostasis comprising the steps of:

- (a) accessing a surgical site;
- (b) performing a surgical procedure; and
- (c) placing the composition of claim 1 in contact with a bleeding tissue.

5

38. The method of claim 37, wherein said surgical procedure is selected from the group consisting of abdominal, ophthalmic, orthopedic, gastrointestinal, thoracic, cranial, cardiovascular, gynecological, urological, plastic, musculoskeletal, spinal, nerve, tendon, otorhinolaryngological and pelvic.

10

39. The method of claim 37, wherein said surgical procedure is selected from the group consisting of appendectomy, cholecystectomy, hernial repair, lysis of peritoneal adhesions, kidney surgery, bladder surgery, urethral surgery, prostate surgery, salpingostomy, salpingolysis, ovariolysis, removal of endometriosis, surgery to treat ectopic pregnancy, myomectomy of uterus, myomectomy of fundus, hysterectomy, laminectomy, discectomy, tendon surgery, spinal fusion, joint replacement, joint repair, strabismus surgery, glaucoma filtering surgery, lacrimal drainage surgery, sinus surgery, ear surgery, bypass anastomosis, heart valve replacement, thoracotomy, synovectomy, chondroplasty, removal of loose bodies and resection of scar tissue.

15

40. The method of claim 37, wherein said step of accessing is carried out using an arthroscope.

20

41. A method for decreasing post-traumatic bleeding, comprising the step of delivering to a site of trauma the composition of claim 1.

42. The method of claim 41, further comprising, prior to the step of delivering, the step of accessing a site of trauma.

43. A method for decreasing bleeding caused by a surgical instrument, 5 comprising coating said surgical instrument with the composition of claim 1 prior to using said surgical instrument.

44. A dried hemostatic membrane comprising a composition of claim 1.

10 45. The dried hemostatic membrane of claim 44, which possesses at least one additional property selected from the group consisting of bioresorbability, bioadhesiveness, antithrombogenicity, and antiadhesion, and wherein the composition has a pH in the range of about 2.5 to about 7.5 and is hydratable by at least about 100%.

15 46. The membrane of claim 44, wherein the PA is a CPS selected from the group consisting of carboxymethyl cellulose (CMC), carboxyethyl cellulose, chitin, carboxymethyl chitin, hyaluronic acid, alginate, propylene glycol alginate, carboxymethyl chitosan, pectin, carboxymethyl dextran, heparin, heparin sulfate, 20 chondroitin sulfate and polyuronic acids including polymannuronic acid, polyglucuronic acid and polyguluronic acid.

47. The composition of claim 44, wherein the molecular weight of the CPS is between 10 kd and 10,000 kd.

25 48. The composition of claim 44, wherein said PO is a PE having a molecular weight between about 200d and about 8000 kd.

49. The composition of claim 44, wherein the CPS is CMC.

50. The composition of claim 48, wherein the PE is polyethylene oxide (PEO).

5 51. The composition of claim 44, wherein the proportion of total solids content of the CPS is from 10 % to 99 % by weight, and the proportion of the PE is from 1 % to 90 % by weight.

10 52. The composition of claim 44, wherein the degree of substitution of the CPS is from greater than about 0 up to and including about 3.

53. The composition of claim 44 further comprising a drug.

15 54. The composition of claim 53, wherein said drug is selected from the group consisting of antibiotics, hemostatic agents, anti-inflammatory agents, hormones; chemotactic factors, peptides and proteins containing an RGD motif, analgesics, and anesthetics.

55. The composition of claim 44, further comprising a plasticizer.

20 56. The composition of claim 55, wherein the plasticizer is selected from the group consisting of glycerol, ethanolamines, ethylene glycol, 1,2,6-hexanetriol, monoacetin, diacetin, triacetin, 1,5-pentanediol, PEG, propylene glycol, and trimethylol propane.

25 57. The composition of claim 55, wherein the concentration of said plasticizer is in the range of greater than about 0 % to about 30 % by weight.

58. The composition of claim 55, wherein the plasticizer is glycerol in a concentration in the range of about 2 % to 30 % by weight.

59. The composition of claim 44, wherein the adherence of platelets to the surface of said composition is in the range of about 0 platelets per 25,000 μm^2 to about 65 per 25,000 μm^2 .

60. The composition of claim 1, wherein the bleeding time is reduced from that of untreated tissues by at least 1/2.

10 61. The method of claim 27, further comprising the step of sterilizing the composition by autoclaving, γ -irradiation, filtration, or exposure to ethylene oxide.

15 62. The method of claim 37, wherein said step of placing said composition is accomplished using an endoscope.

63. The composition of claim 1, wherein the pH of said composition is below about 5.0.

20 64. The composition of claim 1, wherein the pH of said composition is below about 4.0.

25 65. The composition of claim 1, wherein the pH of said composition is below about 3.0.

66. A composition comprising an association complex of a polyacid (PA), a polyalkylene oxide (PO) and a multivalent cation, which is hemostatic and

possesses at least one additional property selected from the group consisting of antiadhesion, bioadhesiveness, antithrombogenicity and bioresorbability, and wherein the pH of said composition is below about 7.5.

5

67. The composition of claim 66, wherein said multivalent cation is selected from the group consisting of Ca^{2+} , Mg^{2+} , Mn^{2+} , Fe^{3+} , Cr^{3+} , Zn^{2+} and Al^{3+} .

68. The composition of claim 66, wherein said multivalent cation is Ca^{2+} .

10

69. A method for manufacturing a hemostatic composition, comprising the steps of:

- (a) selecting a polyacid;
- (b) selecting a polyalkylene oxide;
- (c) forming a solution of said polyacid and said polyalkylene oxide;
- (d) adding a multivalent cation; and
- (e) adjusting the pH of said composition to the range of below about 7.5.

20

70. The method of claim 69, wherein said multivalent cation is selected from the group consisting of Ca^{2+} , Mg^{2+} , Mn^{2+} , Fe^{3+} , Cr^{3+} , Zn^{2+} and Al^{3+} .

71. The method of claim 69, wherein said multivalent cation is Ca^{2+} .

25

72. The composition of claim 1, further comprising thrombin.

73. The composition of claim 1, wherein said polyalkylene oxide is polyethylene glycol having a molecular weight in the range of about 1000 Daltons to about 40,000 Daltons.
- 5 74. The composition of claim 1, wherein said polyalkylene oxide is polyethylene glycol having a molecular weight in the range of about 1000 Daltons to about 20,000 Daltons.
- 10 75. The composition of claim 44, wherein the molecular weight of the CPS is between bout 10 kd and 1000 kd.
76. The composition of claim 1, further comprising thrombin.
- 15 77. The composition of claim 1, further comprising a vasoconstrictor.
78. The composition of claim 77, wherein said vasoconstrictor is an adrenergic agonist.
- 20 79. The composition of claim 78, wherein said adrenergic agonist is selected from the group consisting of norepinephrine, epinephrine, phenylpropanolamine, dopamine, metaraminol, methoxamine, ephedrine, and propylhexedrine.
80. The composition of claim 1, further comprising fibrillar collagen.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/13520

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/74, 38/46, 38/48, 9/70, 9/14, 38/00, 47/30, 47/32, 47/34, 47/00
US CL : 424/78.06, 94.62, 94.64, 443, 449, 487, 488; 514/2, 772.1, 777, 944

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 424/78.06, 94.62, 94.64, 443, 449, 487, 488; 514/2, 772.1, 777, 944

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	US 6,096,309 A (PRIOR et al.) 01 August 2000, (01.08.00), see abstract, column 1, lines 15-18, column 2, lines 61-64, column 3, lines 1-9, column 3, lines 26-37, column 3, lines 45-57, column 4, lines 6-18, column 4, lines 64-67, column 8, lines 53-67, column 10, line 17 to column 11, line 47.	1-80
X	US 6,054,122 A (MACPHEE et al.) 25 April 2000 (25.04.00) see entire document	1-80
Y	US 5,968,542 A (TIPTON, A.) 19 October 1999 (19.10.99) see abstract, column 2, ones 49-58, column 7, line 5 to column 8, line 36, column 9, lines 25-60, column 11, line 31 to column 12, line 34, column 12, lines 56-63, example 26, column 22, lines 51-56, see claim 14.	1-80
A	US 5,944,754 (VACANTI, C.) 31 August 1999 (31.08.99) see entire document.	1-80
Y	US 5,858,746 A (HUBBELL et al.) 12 January 1999 (12.01.99) see abstract, column 1, line 65 to column 2, line 3, column 4, lines 15-25, column 5, line 35 to column 6, line 42, especially column 6, lines 20-32, column 8, lines 30-30, column 13, lines 25-41, column 14, line 56 to column 15, line 10, column 29, lines 11-25, see claim 7	1-80
Y	US 5,512,329 A (GUIRE et al.) 30 April 1996 (30.04.96) see column 2, line 56 to column 4, line 2, see claim 15.	1-15
—		-----
A		16-80

Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 18 June 2001 (18.06.2001)	Date of mailing of the international search report 10 SEP 2001
--	--

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer TERRY J. DEY Donna A. Jagoe PARALEGAL SPECIALIST  Telephone No. (703)305-0193
--	---

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/13520

Continuation of B. FIELDS SEARCHED Item 3: WEST 2.0, search terms: hemostat\$3, antiadhesion, polyacid, carboxypolysaccharide or polyacrylic or polyamino or polylactic or polyglycolic or polymethacrylic or polyterephthalic or polyhydroxybutyric or polyphosphoric or polystyrenesulfonic, polyalkylene oxide, carboxymethylcellulose or cmc or carboxyethylcellulose or chitin or carboxymethyl chitin or hyaluronic acid or hyaluron or alginate or propylene glycol alginate or pectin or carboxymethyl dextran or carboxymethyl chitosan or heparin or chondroitin or polyuronic acid or polyna??uronic acid or polyglucuronic acid or polyguluroc acid, polypropylene oxide or polyethylene glycol or PEG or polyethylene oxide or PEO/PPO block copolymer, antiadhesion, antithromb?, hemostat?, trivalent cation, divalent cation, gel, iron or fe? or aluminum or al? or chromium or cr or calcium or ca? or zinc or zn? or magnesium or mg? or manganese or mn?, antiinflammatory or hormone or chemotactic or analgesic or growth factor or cytokine or osteogenic factor or anesthetic, vasoconstrictor.